Etude STORM

Etude randomisée multicentrique du traitement de récupération des cancers de la prostaste oligométastatiques (STORM- trial).

Indication 

Cancer de la prostate oligométastatique 

Phase I/II

Status : ouverte à l'inclusion

Sponsor
Ghent University, Ghent, Belgium - Professor  Piet Ost

Investigateur
Dr Thomas Zilli -
Service de radio-oncologie HUG
Avenue de la Roseraie 53
1205 Genève
Tél. +4122 37 27 132

Consulter le protocole de l'étude >>

 

Objectives

Primary Objective:
-To compare metastases-free survival (MFS) between metastasis-directed therapy and metastasis-directed therapy with whole pelvis radiotherapy for oligorecurrent nodal prostate cancer.
Secondary Objectives:
- To compare clinical progression-free survival between arms
- To compare biochemical progression between arms
- To compare late toxicity between arms
- To compare the quality of life between arms.
- To compare the relapse pattern between arms
- To compare time to start of palliative ADT, time to castration-resistant disease and overall survival between arms
- Economical evaluation of different treatment arms
- Sensitivity and specificity of imaging modality for patients receiving sLND as MDT
- Biomarker discovery: To develop a miRNA panel predictive for treatment response using whole genome miRNA expression profiling.

 

< RETOUR

Dernière mise à jour : 29/01/2019